https://www.selleckchem.com/products/jib-04.html
Ibrutinib has now been approved for treatment of chronic lymphocytic leukemia (CLL) in both front-line setting and as later-line treatment. However, knowledge about the outcomes and adverse events (AE) among patients at a population-based level is still limited. To report outcomes and AEs in a population-based cohort treated with ibrutinib outside clinical trials. We conducted a multicenter, retrospective cohort study including all patients with CLL treated with ibrutinib. In total, 205 patients were included of whom 39 (19%) were treatm
Like
Comment
Share
